Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Healthy brain in a healthy body3549
Diversity and inclusion in neurosurgery785
Score fluctuation might be associated with a higher placebo rate in the RAISE trial537
Challenges of Parkinson's disease GWASs in African people506
The hidden unity of the mind477
Kerstin Hellwig: educating on multiple sclerosis and pregnancy440
Treatment of asymptomatic carotid stenosis in SPACE-2410
With thanks to our peer reviewers in 2022342
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply321
Transforming amyotrophic lateral sclerosis into a liveable disease303
Elevating the wellbeing of neurologists299
Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke294
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial287
The reality of multiple sclerosis assessment in middle-income countries285
The debate on how to protect and restore brain health282
Disparities in neurosurgical care for traumatic brain injury266
Advanced consent for acute stroke trials263
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial234
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial226
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-in222
The challenge of pregnancy in women with multiple sclerosis217
Cardiovascular disease after traumatic brain injury: the heart of the matter212
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial211
Maxime Baud203
A neurological journey to save lives in Haiti195
Medieval treatment of epilepsy in England193
Lightning progress in child neurology in the past 20 years190
Spiralling towards an ending168
Tanuja Chitnis: on role models, family, and multiple sclerosis168
Dancing with paper160
Anatomy embroiders function in Purkinje cells155
Malformations of cortical development as models of altered brain excitability154
Seizure prevention in patients with intracerebral haemorrhage153
Maeike Zijlmans147
Vittorio Marchi's staining146
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA146
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation145
The wisdom of our mentors: clinical pearls in movement disorders143
Pseudomedicine for sports concussions in the USA142
Licence to practise141
Our Dementia Choir hits the right notes136
Fetal exposure to antiseizure medications: reassurance and concerns131
CGRP-targeted drugs for migraine: still many uncertainties131
Elisaveta Sokolov128
Sex, gender, and the cost of neurological disorders127
Journey down memory lane125
V Wee Yong: a journey of rediscovery124
Giuseppe Citerio's neurocucina123
Form and function in the brain122
The social network of functional neurological disorder121
Tatyana Shelkovnikova121
COP27 Climate Change Conference: urgent action needed for Africa and the world117
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions117
The link between blood pressure and Alzheimer's disease116
Multiple sclerosis: two decades of progress115
Traumatic brain injury research: homogenising heterogeneity111
α-synuclein seed amplification in Parkinson‘s disease109
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study108
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 105
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage102
PROMISE of low-cost immunosuppressants for myasthenia gravis97
The predictive value and clinical use of the neurological pupillary index – Authors' reply96
Monitoring patients with severe traumatic brain injury95
Innovation in the prevention of neurological diseases93
A contentious FDA ruling for Alzheimer's disease92
Dementia care: beyond a diagnosis92
Advancing seizure forecasting from cyclical activity data92
Huntington's disease: disappointments and new beginnings90
Climate change and neurology: time to talk and to act89
Lessons and future directions for GBA1-targeting therapies88
Georgios Tsivgoulis: in top gear87
Intracranial pressure monitoring and unfavourable outcomes86
20th Anniversary photography competition: neurology for zoomers80
Leriglitazone: frustration and hope in adrenoleukodystrophy79
The East Asian Parkinson Disease Genomics Consortium79
Headache in 2021: clinical, biological, and genetic advances79
Intra-arterial bone marrow mononuclear cells for stroke77
0.13756704330444